Common adverse effects that are associated with<unk>  and other anticholinergics include: dry mouth, difficulty in urination, constipation, blurred vision, drowsiness, and dizziness. Anticholinergics have also been known to induce delirium.<unk> 's tendency to reduce sweating can be dangerous. Reduced sweating increases the risk of heat exhaustion and heat stroke in apparently safe situations where normal sweating keeps others safe and comfortable. Adverse effects of elevated body temperature are more likely for the elderly and for those with health issues, especially multiple sclerosis. N-Desethyloxybutynin is an active metabolite of<unk>  that is thought responsible for much of the adverse effects associated with the use of<unk> . N-Desethyloxybutynin plasma levels may reach as much as six times that of the parent drug after administration of the immediate-release oral formulation. Alternative dosage forms have been developed in an effort to reduce blood levels of N-desethyloxybutynin and achieve a steadier concentration of<unk>  than is possible with the immediate release form. The long-acting formulations also allow once-daily administration instead of the twice-daily dosage required with the immediate-release form. The transdermal patch, in addition to the benefits of the extended-release oral formulations, bypasses the first-pass hepatic effect that the oral formulations are subject to. In those with overflow incontinence because of diabetes or neurological diseases like multiple sclerosis or spinal cord trauma,<unk>  can worsen overflow incontinence since the fundamental problem is that the bladder is not contracting. A large study linked the development of dementia in those over 65 to the use of<unk> , due to its anticholinergic properties.
Oxybutynin
Xylometazoline
Acebutolol
Tamsulosin
Oxymetazoline
Hyoscine butylbromide
Tolbutamide
Hydrastine